Renalytix Plc (LON:RENX – Get Free Report) shares rose 14.2% on Monday . The company traded as high as GBX 2.80 and last traded at GBX 2.65. 7,356,022 shares changed hands during mid-day trading, an increase of 719% from the average daily volume of 897,943 shares. The stock had previously closed at GBX 2.32.
Renalytix Price Performance
The company has a current ratio of 1.21, a quick ratio of 2.42 and a debt-to-equity ratio of -118.57. The stock has a 50-day moving average price of GBX 1.83 and a 200 day moving average price of GBX 3.37. The stock has a market capitalization of £11.58 million, a price-to-earnings ratio of -0.66 and a beta of 1.79.
About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).
Recommended Stories
- Five stocks we like better than Renalytix
- Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors
- Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and Grains
- This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street
- AI Is Selling Off, But These 5 Stocks Could Benefit Next
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.
